1. Proliferation in HHV-8-Positive Primary Effusion Lymphomas Is Associated with Expression of HHV-8 Cyclin but Independent of p27(kip1).
2. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study.
3. Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & Tumori.
4. Molecular profile of epstein-barr virus infection in HHV-8-positive primary effusion lymphoma.
5. Lung carcinoma in 36 patients with human immunodeficiency virus infection.
6. Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
7. Idiopathic chronic fatigue and chronic fatigue syndrome: a comparison of two case-definitions.
8. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy.
9. Neoplastic complications of HIV infection.
10. Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection.
11. Interactions of Antineoplastic Chemotherapy with Zidovudine Pharmacokinetics in Patients with HIV-Related Neoplasms.
12. Hodgkin's disease in HIV-infected individuals.
13. Combination therapy with alpha interferon and lamivudine in patients with chronic hepatitis B and HIV infection.
14. Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2.
15. Debate on Di Bella therapy.
16. Evaluation study of the opinion on Di Bella's multimodal therapy of patients with tumors.
17. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
18. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.
19. The effects of CD40 ligation on peripheral blood mononuclear cell interleukin-12 and interleukin-15 production and on monocyte CD14 surface antigen expression in human immunodeficiency virus-positive patients.
20. AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients.
21. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.
22. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells.
23. Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients.
24. Condom use in female sex workers in Italy.
25. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
26. The pathologic spectrum of AIDS-related non-Hodgkin’s lymphomas.
27. Major cardiovascular events following infusional 5-fluorouracil and cisplatin antineoplastic therapy.
28. Neoplastic disease.
29. The role and activity of an Italian volunteer organization providing information and emotional support for patients with cancer.
30. Discordant hhv8 detection in a young hiv-negative patient with kaposi's sarcoma and sarcoidosis.
31. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy.
32. Hodgkin's disease: clinical presentation and treatment.
33. A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.
34. A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.
35. Primary effusion lymphoma cell lines harbouring human herpesvirus type-8.
36. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma.
37. Human immunodeficiency virus-associated Hodgkin's disease.
38. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy.
39. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral Naive Patients.
40. Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
41. Effects of 2-year antiretroviral combination therapies on HIV-1 DNA levels.
42. Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ at lymphocyte apoptosis in HIV+patients.
43. Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection.
44. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin lymphoma.
45. Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individualks with known date of seroconversion.
46. Hodgkin's disease: clinical presentation and treatment.
47. A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute.
48. Discordant hhv8 detection in a young HIV-negative patient with Kaposi's sarcoma and sarcoidosis.
49. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and combination therapy.
50. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC Study.
51. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.
52. Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy.
53. Response to highly active antiretroviral therapy according to duration of HIV infection.
54. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotehrapy.
55. Human immunodeficiency virus-related non-Hodgkin's lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients.
56. Impact of HAART on the clinical management of AIDS-related cancers.
57. Clinical aspects and management of Hodgkin's disease and other tumors in HIV-infected individuals.
58. Chronic hepatitis C in HIV-coinfected patients: feasibility and sustained efficacy of therapy with interferon alpha-2b and ribavirin.
59. Cervical cancer in HIV.
60. Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy.
61. I linfomi non-Hodgkin-HIV sistemici nell'era dell'HAART. Storia naturale.
62. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.
63. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
64. Neoplastic complications of AIDS.
65. AIDS-related tumors: integrating antiviral and anticancer therapy.
66. Relevance of intraocular involvement in the management of primary central nervous system lymphomas.
67. Elderly head and neck (H-N) cancer patients: a monoinstitutional series.
68. Non-Hodgkin's lymphoma in the elderly.
69. Hodgkin's disease in the elderly: current status and future directions.
70. A multicenter study of treatment of primary CNS lymphoma.
71. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose intensity of doxorubicin and cyclophosphamide
72. Differentation between non-Hodgkin's lymphoma ercurrence and second primary lymphoma by VDJ rearrangement analysis.
73. Expression of cyclin-dependent kinase inhibitor p27Kip1 in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.
74. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
75. Cancer-related fatigue.
76. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma.
77. No Protective effects of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals.
78. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
79. Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters.
80. Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan.
81. Rituximab and chemotherapy is highly effective in patients with CD20-positive non Hodgkin's lymphoma and HIV infection.
82. High international prognostic score predicts a worse outcome for patients with Hodgkin's disease and HIV infection: results of a prospective study with Stanford V regimen.
83. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type.
84. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
85. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
86. Hodgkin's disease in HIV.
87. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals
88. Therapeutic approaches to AIDS-related malignancies
89. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin's lymphoma.
90. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.
91. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single institution study
92. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy.
93. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi’s sarcoma.
94. Outcome in patients with no-hodgkin lymphoma and with or without human immunodeficiency virus infection
95. Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials
96. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial
97. Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treat with antiblastic chemotherapy and highly active antiretroviral therapy
98. Efficacy and safety of combined treatment with pegylated.IFN-alpha2b plus rebavirin in HIV-hepatitis C virus-co-infected patients
99. Improving information to Italian cancer patients: results of a randomized study
100. Tumori solidi
101. HIV-related non-Hodgkin's lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management.
102. Rituximab-CHOP or 2 weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
103. Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV related non-Hodgkin's lymphoma
104. Fatigue in cancer patients receiving chemotherapy: analysis of published studies.

Fatigue in Cancer - review
105. Rituximab plus infusional cyclophosphamide, doxorubicin and etoposide (R-CDE) in HIV-associated non-Hodgkin's lymphoma: pooled results from three phase II trials.
106. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
107. Treatment of head and neck cancer in elderly patients: state of the art and guidelines.
108. Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus Type 8-Positive Solid Lymphomas: A Tissue-Based Variant of Primary Effusion Lymphoma.
109. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy.
110. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
111. Hepatitis C virus and non-Hodgkin's lymphoma 10 years later.
112. Is high-dose chemotherapy with peripheral stem cell rescue a suitable option for elderly patients affected by aggressive non-Hodgkin's lymphoma?
113. Cancer Prevention and Early Diagnosis in HIV-Positive Individuals.
114. Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma (KS): Implications for the Design of Therapeutic Trials in Patients With Advanced Symptomatic KS.
115. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
116. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
117. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
118. Trends in cancer incidence rates among HIV-infected patients.
119. Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
120. Cancer and aging: are there any differences in the information needs of elderly and younger patients? Results from an Italian observational study.
121. Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
122. Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days.
123. KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.
124. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.
125. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
126. Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era.
Liver resection of metastasis by colorectal cancer in a HIV patient.
128. Oxaliplatin-based chemotherapy in association with highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients
129. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas.
130. Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection.
131. Keynote comment: reimbursement for molecularly targeted anticancer agents
132. A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin.
133. AIDS-related non-Hodgkin's lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
134. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
135. Treatment of elderly cancer patients: a planet in evolution.
136. Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART era.
137. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
138. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention.
139. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era.
140. Insight into the treatment of cancer in older patients: Developments in the last decade.
141. FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients.
142. Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature.
143. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
144. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma
145. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
146. What elderly cancer patients want to know? Differences among elderly and young patients
147. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
148. A pilot project of a cancer patient library in Italy: results of a customer-satisfaction survey and its products.
149. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Haematologica. 2007 Jan;92(1):35-41.
150. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
Eur J Haematol. 2007 Jan 23
151. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
J Clin Oncol. 2007 Feb 20;25(6):e7.
152. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
J Chemother. 2007 Jun;19(3):343-6.
153. Lopinavir-Ritonavir Dramatically Affects the Pharmacokinetics of Irinotecan in HIV Patients With Kaposi's Sarcoma.
Clin Pharmacol Ther. 2007 Aug 22
154. Role of the HLA class II: HCV-related disorders.
Ann N Y Acad Sci. 2007 Jun;1107:308-18.
155. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
Bone Marrow Transplant. 2007 Oct 1
156.Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation.
Clin Exp Immunol. 2007 Oct 11
157. High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma.
Leuk Lymphoma. 2007 Oct 9
158. Bearz A, Serraino D, Fratino L, Berretta M, Tirelli U.
Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Cancer. 2007 Oct 25
159. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
N Engl J Med. 2007 Nov 8;357(19):1916-27
160. Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study.
Lung Cancer. 2007 Nov 16
161. Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia.
Dig Liver Dis. 2007 Sep;39 Suppl 1:S102-6.
162. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma.
Int J Cancer. 2007 Dec 4
163. MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients.
Int J Biol Markers. 2007 Oct-Dec;22(4):307-11.
164. Clinical management of long-term cancer survivors.
J Clin Oncol. 2008 Jan 1;26(1):161-2
165. Can the caregiver replace his/her elderly cancer patient in the physician-patient line of communication?
Support Care Cancer. 2008 Jan 29
166. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.
Blood. 2008 May 15;111(10):5142-51.
167. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Lancet. 2008 Apr 26;371(9622):1417-26.
168. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals.
AIDS Patient Care STDS. 2008 Apr;22(4):291-9.
169. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Clin Infect Dis. 2008 Apr 1;46(7):1101-10.
Cancer survivorship: a challenge for the European oncologists.
Ann Oncol. 2008 Jun 4
171. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis.
Haematologica. 2008 Jun 12
172. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients.
Arch Gerontol Geriatr. 2008 Jun 21
173. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
Cancer Invest. 2008 Jul;26(6):610-4. Review.
174. Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Onkologie. 2008 Jul;31(7):394-7
175. FOSFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
J Chemother. 2008 Aug;20(4):503-8.
176. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.
AIDS. 2008 Sep 12;22(14):1769-78
177. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
Br J Cancer. 2008 Sep 9.
178. Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature.
Tumori. 2008 Jul-Aug;94(4):589-91.
179. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
AIDS. 2008 Oct 18;22(16):2143-53.
180. Does short-term virologic failure translate to clinical events in antiretroviral-na�ve patients initiating antiretroviral therapy in clinical practice?
AIDS. 2008 Nov 30;22(18):2481-92.
181. Cancer in the elderly: The caregivers' perception of senior patients' informational needs.
Arch Gerontol Geriatr. 2008 Dec 11.
182. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas
Br J Haematol. 2009 Feb 12.
183. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51.
184. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
J Med Virol. 2009 May;81(5):888-96.
185. Safety and feasibility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients.
Arch Gerontol Geriatr. 2009 Apr 30.
Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.
J Chemother. 2009 Apr;21(2):215-8.
187. Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature.
Hum Pathol. 2009 May 6.
188. High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long term results of the GICAT study with analysis of prognostic factors.
Blood. 2009 May 18.
189. Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study.
Onkologie. 2009 Jun;32(6):319-24. Epub 2009 May 14.
Comment in: Onkologie. 2009 Jun;32(6):306-7.
190. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81.
191. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
Clin Infect Dis. 2009 Aug 15;49(4):612-22.
Comment in: Clin Infect Dis. 2009 Aug 15;49(4):623-5.
192. Glioblastoma in elderly patients: Safety and efficacy of adjuvant radiotherapy with concomitant temozolomide.
Arch Gerontol Geriatr. 2009 Jul 21.
193. Activity of Pemetrexed on brain metastases from Non-Small Cell
.Lung Cancer. 2009 Jul 24.
194. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
Ann Oncol. 2009 Aug;20(8):1445.
Comment on: Ann Oncol. 2009 Mar;20(3):403-12.
195. Assessing cancer-related fatigue: the psychometric properties of the Revised Piper Fatigue Scale in Italian cancer inpatients.
Support Care Cancer. 2009 Sep 26.
196. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Lancet Oncol. 2009 Oct 12.
197. Genome wide DNA-profiling of HIV-related B-cell lymphomas.
Br J Haematol. 2009 Oct 12.
198. Management of immunocompetent patients with primary central nervous system lymphoma.
Clin Lymphoma Myeloma. 2009 Oct;9(5):353-64.
199. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.
Collaborators (353)
AIDS. 2009 Nov 27;23(18):2485-95.
200. AIDS-Related Kaposi's Sarcoma: State of the Art and Therapeutic Strategies.
Curr HIV Res. 2009 Nov;7(6):634-8.
201. Comprehensive cancer control-research & development: knowing what we do and doing what we know.
Tumori. 2009 Sep-Oct;95(5):610-22.
202. Biomarkers in neuroendocrine tumors.
Front Biosci (Schol Ed). 2010 Jan 1;2:332-42.
203. Biological and clinical markers in colorectal cancer: state of the art.
Front Biosci (Schol Ed). 2010 Jan 1;2:422-31.
204. Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer: A retrospective analysis.
Arch Gerontol Geriatr. 2009 Dec 29.
205. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.
Cancer. 2010 Jan 27.
206. Predictive Value of HIV Type 1 DNA Levels on Overall Survival in HIV-Related Lymphoma Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).
AIDS Res Hum Retroviruses. 2010 Feb;26(2):245-51.
207. Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study.
Onkologie. 2009 Jun;32(6):319-24.
208. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study.
Arch Gerontol Geriatr. 2010 Mar 6.
209. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.
Clin Infect Dis. 2010 May 1;50(9):1316-21.
210. HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population.
Onkologie. 2010;33(4):203-4.
211. Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma.
Clin Infect Dis. 2010 Jun 15;50(12):1672-9.
212.Biomarkers in lung cancer.
Front Biosci (Elite Ed). 2010 Jun 1;2:1099-104
213.The revised piper fatigue scale (PFS-R) for Italian cancer patients: a validation study.
Tumori. 2010 Mar-Apr; 96(2):276-81.